Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Maintenance Kidney Transplant

Conditions

Maintenance Kidney Transplant

Trial Timeline

Jul 1, 2006 → Sep 1, 2008

NCT ID

NCT00400647

About Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil

Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil is a approved stage product being developed by Novartis for Maintenance Kidney Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT00400647. Target conditions include Maintenance Kidney Transplant.

What happened to similar drugs?

6 of 20 similar drugs in Maintenance Kidney Transplant were approved

Approved (6) Terminated (2) Active (12)

✅Zolpidem MR + EstazolamAstellas PharmaApproved

✅Zolpidem MR + Zolpidem IRAstellas PharmaApproved

✅Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved

✅Cyclosporine - cyclosporine microemulsionNovartisApproved

✅Enteric-coated Mycophenolate sodium (EC-MPS)NovartisApproved

✅ZolpidemSanofiApproved

🔄zolpidem MR + nitrazepam + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00400647	Approved	Completed	Jul 1, 2006	Sep 1, 2008	Maintenance Kidney Transplant

Competing Products

20 competing products in Maintenance Kidney Transplant

See all competitors

Product	Company	Stage	Hype Score
LY2422347 + placebo	Eli Lilly	Phase 2	35
LY2624803 - Solution + LY2624803 - Capsule + Placebo - Solution + Placebo - Capsule	Eli Lilly	Phase 1	29
Zolpidem MR + Estazolam	Astellas Pharma	Approved	43
zolpidem MR + nitrazepam + placebo	Astellas Pharma	Phase 3	40
FK199B + Zolpidem	Astellas Pharma	Phase 3	40
ASP7991	Astellas Pharma	Phase 1	29
Graceptor®	Astellas Pharma	Pre-clinical	26
Zolpidem MR + Zolpidem IR	Astellas Pharma	Approved	43
Zolpidem MR + Zolpidem	Astellas Pharma	Phase 3	40
Lemborexant	Eisai	Phase 2	35
Lemborexant + Placebo	Eisai	Phase 3	40
Lemborexant	Eisai	Pre-clinical	26
Eszopiclone + Fluoxetine + Placebo	Sumitomo Pharma	Approved	43
Org 50081 + Org 50081 + Placebo + zopiclone	Merck	Phase 1	29
esmirtazapine	Merck	Phase 3	32
Esmirtazapine	Merck	Phase 3	40
Suvorexant + Placebo	Merck	Phase 3	40
Esmirtazapine + Placebo	Merck	Phase 3	40
Cyclosporine - cyclosporine microemulsion	Novartis	Approved	43
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	43